Cargando…
The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
INTRODUCTION: Soluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cel...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687412/ https://www.ncbi.nlm.nih.gov/pubmed/38033491 http://dx.doi.org/10.3389/fonc.2023.1194315 |
_version_ | 1785151972334108672 |
---|---|
author | Yoon, Sang Eun Park, Sujin Cho, Junhun Ryu, Kyung Ju Yandava, Booma Lee, Sewon Kim, Seok Jin Kim, Won Seog |
author_facet | Yoon, Sang Eun Park, Sujin Cho, Junhun Ryu, Kyung Ju Yandava, Booma Lee, Sewon Kim, Seok Jin Kim, Won Seog |
author_sort | Yoon, Sang Eun |
collection | PubMed |
description | INTRODUCTION: Soluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cell lymphoma (ND-DLBCL). METHODS: We analyzed sMICA/sMICB, cytokine in serum, and macrophage polarization analysis in tissue samples before the first chemotherapy administration. This research was performed to investigate the correlation between sMICA/sMICB expression and treatment outcomes as well as their influence on the immune system within ND-DLBCL. RESULTS: Of the 262 patients, 47.3% (n = 124) presented stage III or IV at diagnosis and 50.8% (n = 133) had a high International Prognostic Index (IPI ≥ 3). The patients with high (p = 0.034 and 0.004), elevated lactate dehydrogenase (p = 0.002 and 0.030), advanced stage (p = 0.003 and 0.012), and higher IPI risk (p = 0.009, and 0.032) correlated with the detection of sMICA or sMICB. The median progression-free survival (PFS) of patients with sMICA (p = 0.006) or sMICB (p =0.032) was inferior. Among the patients with advanced-stage or high IPI, those with sMICA or sMICB presented an inferior PFS and OS compared to those without. TNF-a, a pro-inflammatory cytokine, showed statistical significance with detected sMICA (p = 0.035) or sMICB (p = 0.044). Among anti-inflammatory cytokines, IL-1RA (P-value = 0.013) and IL-10 (p = 0.005) were associated with detecting sMICB, but not sMICA. In tissue samples, sMICA or sMICB detection did not correlate with the CD68/CD163 ratio. DISCUSSION: Conclusively, the identification of sMICA/sMICB presented unfavorable immunochemotherapy outcomes, and it was assumed that sMICA or sMICB and various cytokines interact, but the relationship with macrophage differentiation is unclear. Therefore, further research is needed to determine the relationship between sMICA/sMICB and tumor microenvironment in DLBCL. |
format | Online Article Text |
id | pubmed-10687412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106874122023-11-30 The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma Yoon, Sang Eun Park, Sujin Cho, Junhun Ryu, Kyung Ju Yandava, Booma Lee, Sewon Kim, Seok Jin Kim, Won Seog Front Oncol Oncology INTRODUCTION: Soluble MHC class I-related chain A (sMICA) and B (sMICB) play a critical role tumor evolution and poor prognosis through an immune evasion mechanism. Thus, this study determines the interaction between sMICA/sMICB and the tumor immune environment in newly diagnosed diffuse large B-cell lymphoma (ND-DLBCL). METHODS: We analyzed sMICA/sMICB, cytokine in serum, and macrophage polarization analysis in tissue samples before the first chemotherapy administration. This research was performed to investigate the correlation between sMICA/sMICB expression and treatment outcomes as well as their influence on the immune system within ND-DLBCL. RESULTS: Of the 262 patients, 47.3% (n = 124) presented stage III or IV at diagnosis and 50.8% (n = 133) had a high International Prognostic Index (IPI ≥ 3). The patients with high (p = 0.034 and 0.004), elevated lactate dehydrogenase (p = 0.002 and 0.030), advanced stage (p = 0.003 and 0.012), and higher IPI risk (p = 0.009, and 0.032) correlated with the detection of sMICA or sMICB. The median progression-free survival (PFS) of patients with sMICA (p = 0.006) or sMICB (p =0.032) was inferior. Among the patients with advanced-stage or high IPI, those with sMICA or sMICB presented an inferior PFS and OS compared to those without. TNF-a, a pro-inflammatory cytokine, showed statistical significance with detected sMICA (p = 0.035) or sMICB (p = 0.044). Among anti-inflammatory cytokines, IL-1RA (P-value = 0.013) and IL-10 (p = 0.005) were associated with detecting sMICB, but not sMICA. In tissue samples, sMICA or sMICB detection did not correlate with the CD68/CD163 ratio. DISCUSSION: Conclusively, the identification of sMICA/sMICB presented unfavorable immunochemotherapy outcomes, and it was assumed that sMICA or sMICB and various cytokines interact, but the relationship with macrophage differentiation is unclear. Therefore, further research is needed to determine the relationship between sMICA/sMICB and tumor microenvironment in DLBCL. Frontiers Media S.A. 2023-11-16 /pmc/articles/PMC10687412/ /pubmed/38033491 http://dx.doi.org/10.3389/fonc.2023.1194315 Text en Copyright © 2023 Yoon, Park, Cho, Ryu, Yandava, Lee, Kim and Kim https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yoon, Sang Eun Park, Sujin Cho, Junhun Ryu, Kyung Ju Yandava, Booma Lee, Sewon Kim, Seok Jin Kim, Won Seog The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
title | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
title_full | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
title_fullStr | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
title_full_unstemmed | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
title_short | The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma |
title_sort | impact of smica/smicb on immunochemotherapy outcomes in newly diagnosed diffuse large b-cell lymphoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687412/ https://www.ncbi.nlm.nih.gov/pubmed/38033491 http://dx.doi.org/10.3389/fonc.2023.1194315 |
work_keys_str_mv | AT yoonsangeun theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT parksujin theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT chojunhun theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT ryukyungju theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT yandavabooma theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT leesewon theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT kimseokjin theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT kimwonseog theimpactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT yoonsangeun impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT parksujin impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT chojunhun impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT ryukyungju impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT yandavabooma impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT leesewon impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT kimseokjin impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma AT kimwonseog impactofsmicasmicbonimmunochemotherapyoutcomesinnewlydiagnoseddiffuselargebcelllymphoma |